Bibliography
- De Ruijter AJM, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49
- Foglietti C, Filocamo G, Cundari E, et al. Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281(26):17968-76
- Lee JH, Maskos K, Huber R. Structural and functional studies of the yeast class II Hda1 histone deacetylase complex. J Mol Biol 2009;391(4):744-57
- Jin YH, Jeon EJ, Li QL, et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004;279(28):29409-17
- Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4(1):5
- Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007;26(37):5310-18
- Ververis K, Hiong A, Karagiannis TC, et al. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013;7:47-60
- Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42
- Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32
- Ueki N, Lee S, Sampson NS, et al. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nature Commun 2013;4:2735
- Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13(9):673-91
- Zhang L, Fang H, Xu W. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev 2010;30(4):585-602
- Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. P Natl Acad Sci USA 1998;95(6):3003-7
- Ueda H, Nakajima H, Hori Y, et al. Fr901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium-Violaceum No-968. 1. Taxonomy, Fermentation, Isolation, Physicochemical and Biological Properties, and Antitumor-Activity. J Antibiot 1994;47(3):301-10
- Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002;46(11):3532-9
- Pfaller MA, Messer SA, Georgopapadakou N, et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009;47(12):3797-804